Healthcare and AI provide support in a mixed market environment
Last week presented a mixed picture within the UMBRELLA strategy. While several companies in the healthcare and technology sectors developed positively, European defense stocks came under greater pressure, and SpaceX remained volatile.
Against this backdrop, no adjustments were made via the MUMAK UMBRELLA strategy. The focus remains on healthcare innovation, European defense, artificial intelligence, and advanced technology. Individual positions are subject to updated research based on their fundamental development, market sentiment, and technical picture.
Development of the UMBRELLA Strategy
Healthcare sector continues to provide support
The healthcare sector was again among the supportive areas of the UMBRELLA strategy last week.
Revolution Medicines continued to trade near its record highs. Recent regulatory and clinical progress surrounding Daraxonrasib continues to shape market expectations. The path towards potential commercialization remains a central factor for the company. The comparison and developments around Moderna were interesting here, as both companies are working on a platform basis in oncology.
Also, Eli Lilly developed positively after strong second-quarter results. During the week, the company announced a new collaboration with OmniAb. As part of the global research and licensing agreement, Lilly will utilize OmniAb’s technology platform and expertise for a new ion channel program, thereby expanding its drug discovery activities with another technological approach.
Johnson & Johnson gained during the week and presented MONARCH QUEST 3, the latest advancement of its robotic bronchoscopy platform. The software update expands the MONARCH platform to include improved AI-powered planning and navigation for examining suspicious lung nodules, underscoring the group’s innovation activities in the MedTech sector alongside its pharmaceutical business.
The healthcare positions thus continue to combine different growth drivers – from oncology and pharmaceutical innovation to medical technology.
Palantir continues positive development
Palantir ended the week higher. Continued demand for artificial intelligence and applications for government clients continued to support market sentiment towards the company.
The fundamental dynamics are closely linked to the increasing use of AI applications by commercial and government clients. At the same time, the valuation remains an important factor after the strong share price performance.
For the MUMAK UMBRELLA strategy, therefore, the interplay of operational growth, market expectations, and technical dynamics is particularly relevant. The technical dynamics are particularly striking.
European defense stocks with a weaker week
The European defense positions Rheinmetall, Thales and TKMS were weak.
The overarching structural background of the sector remains unaffected. Rising European defense spending, modernization programs, and growing order backlogs continue to provide long-term visibility within the industry.
For TKMS, the focus is on the implementation of the recently raised annual forecast and the development of the extensive order pipeline. Profit-taking characterized the picture.
Thales remains in focus after its half-year figures. Following the significant share price recovery into August, the recent setback has dampened some of the short-term technical momentum. It will be interesting to see if and when a new bottoming out could occur.
SpaceX remains volatile
SpaceX again experienced a volatile week after another tranche of shares became tradable.
The additional supply temporarily put pressure on the share price, while the company’s operational development continued. Falcon 9 launches and the further expansion of the SpaceX ecosystem remain important indicators for operational dynamics.
Following the recent inclusion of SpaceX in the UMBRELLA strategy, the focus is increasingly on how the market assesses the valuation and long-term growth expectations after the initial price movements since the IPO.
MercadoLibre stabilizes after quarterly figures
MercadoLibre developed more favorably during the week and recovered from the weakness after the latest quarterly figures.
Fundamentally, operational development remains dynamic. In the second quarter, revenue and financial income rose by 50% to $10.2 billion, while both the e-commerce business and Mercado Pago grew strongly. At the same time, the lower operating margin and high investments in logistics, credit business, and customer growth remain important factors for market sentiment.
After the recent share price recovery, the focus is increasingly on whether the technical stabilization continues and whether the market again weighs strong growth more heavily than short-term margin pressure.
No adjustments to the UMBRELLA strategy
The positioning in the MUMAK UMBRELLA strategy remained unchanged last week.
The cash allocation was around 0.6%, meaning the strategy was almost fully aligned with its current key themes.
Outlook for the coming week
After a mixed week, the focus is on the interplay of company-specific developments, economic data, and market dynamics.
In the healthcare sector, Revolution Medicines will particularly focus on further regulatory and clinical developments surrounding Daraxonrasib. For Eli Lilly and Johnson & Johnson, the focus is on continued operational development after the latest corporate news.
In the European defense sector, after the recent weaker share price performance, Rheinmetall, Thales and TKMS remain in focus. The fundamental industry environment continues to be supported by higher defense spending and long-term procurement programs.
For Palantir and SpaceX, market expectations and valuation remain particularly relevant given recent price movements.
The focus of the UMBRELLA strategy thus remains on healthcare innovation, European defense, artificial intelligence, and advanced technology.
New corporate developments, market sentiment, and technical signals remain crucial.
We continuously monitor these factors.
Continue to regularly follow the MUMAK UMBRELLA strategy.
